Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
MSI-H/dMMR + TMB-H
i
Other names:
MSI | Microsatellite instability, TMB | Tumor Mutational Burden
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related biomarkers:
Expression
Mutation
Others
‹
›
Associations
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
MSI-H/dMMR + TMB-H
Solid Tumor
MSI-H/dMMR + TMB-H
Solid Tumor
pucotenlimab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
pucotenlimab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
pucotenlimab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
pucotenlimab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + TMB-H
Colorectal Cancer
MSI-H/dMMR + TMB-H
Colorectal Cancer
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
MSI-H/dMMR + TMB-H
Prostate Cancer
MSI-H/dMMR + TMB-H
Prostate Cancer
avelumab
Sensitive: C4 – Case Studies
avelumab
Sensitive
:
C4
avelumab
Sensitive: C4 – Case Studies
avelumab
Sensitive
:
C4
MSI-H/dMMR + TMB-H
HER2 Positive Breast Cancer
MSI-H/dMMR + TMB-H
HER2 Positive Breast Cancer
pembrolizumab + trastuzumab
Sensitive: C4 – Case Studies
pembrolizumab + trastuzumab
Sensitive
:
C4
pembrolizumab + trastuzumab
Sensitive: C4 – Case Studies
pembrolizumab + trastuzumab
Sensitive
:
C4
MSI-H/dMMR + TMB-H
Gastric Cancer
MSI-H/dMMR + TMB-H
Gastric Cancer
olaparib
Sensitive: D – Preclinical
olaparib
Sensitive
:
D
olaparib
Sensitive: D – Preclinical
olaparib
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login